Generalized Anxiety Disorder Market: By Therapeutics Type(Antidepressant, Benzodiazepines, Others (Buspirone)) & Geography(Europe, Asia Pacific, North America, Rest of the World)-Forecast (2016-2021)
[Lowest Price Guaranteed: $5,250]


Related Topics: GlaxoSmithKline , Pharmaceuticals

Sorry, this report is no longer available.

We may have other suitable reports available - try Searching for Generalized
or contact our sales team for personal assistance: phone +44 (0)7887945155 or email bioportfolio97@gmail.com.

Introduction

Generalized anxiety disorder also known as GAD is diagnosed due to excessive anxiety and worry about individual’s worry about life events with no apparent reason. Individual suffering from GAD keeps on worrying about health, family, money, or work which eventually results into anxiety dominating the person thinking, that interfere with daily functioning of person. GAD is generally identified by symptoms of generalized anxiety disorder, which includes an unrealistic view of problems, muscle tension, headache, sweating, and tiredness.

This report identifies the generalized anxiety disorder market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to generalized anxiety disorder market.


Globally North America dominated the market for generalized anxiety disorder in 2015 with highest market share due to higher research and development activities by pharmaceutical industry in the region. North America was followed by Europe as the second largest regional market for generalized anxiety disorder due to higher patients complaining about stressful life style resulting into GAD. However, Asia-Pacific is expected to remain fastest growing regional segment during the period of study due to changing life style and increasing awareness about such diseases in the region.

This report on global generalized anxiety disorder covers different therapeutics type of generalized anxiety disorder, market size in various geographical regions.

On the basis of therapeutics type of generalized anxiety disorder, this report also covers all the major therapeutics types of generalized anxiety disorder major types covered in this report are as follows: Antidepressant (Selective serotonin reuptake inhibitor (SSRI) and Serotonin norepinephrine reuptake inhibitor(SNRI)), Benzodiazepines (Alprazolam, Chlordiazepoxide, Diazepam, Lorazepam) and Others (Buspirone)

This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for generalized anxiety disorder in each of the region.

This report identifies all the major companies operating in the global generalized anxiety disorder market. Some of the major companies’ profiles in detail are as follows:

GlaxoSmithKline Pharmaceuticals Limited

Bristol-Myers Squibb

Sumitomo Dainippon Pharma

Noven Pharmaceuticals, Inc.

Actavis Pharmaceutical Company

Table of Contents
for Generalized Anxiety Disorder Market: By Therapeutics Type(Antidepressant, Benzodiazepines, Others (Buspirone)) & Geography(Europe, Asia Pacific, North America, Rest of the World)-Forecast (2016-2021)

  • 1. Generalized Anxiety Disorder – Market Overview

    2. Executive Summary

    3. Market Landscape

    3.1. Market Share Analysis

    3.2. Comparative Analysis

    3.2.1. Product Benchmarking

    3.2.2. End User Profiling

    3.2.3. Top 5 Financials Analysis

    4. Generalized Anxiety Disorder – Market Forces

    4.1. Drivers

    4.1.1. Increasing reported cases of HIV, Cancer and cystic fibrosis

    4.2. Restraints

    4.3. Opportunities

    4.4. Challenges

    4.5. Porter’s Five Forces Analysis

    4.5.1. Bargaining Power of Suppliers

    4.5.2. Bargaining Power of Buyers

    4.5.3. Threat of New Entrants

    4.5.4. Threat of Substitutes

    4.5.5. Degree of Competition

    5. Generalized Anxiety Disorder – Strategic Analysis

    5.1. Value Chain Analysis

    5.2. Pricing Analysis

    5.3. Opportunities Analysis

    5.4. Product/Market Life Cycle Analysis

    5.5. Suppliers and Distributors

    6. Generalized Anxiety Disorder Market, By Therapeutics Type

    6.1. Antidepressant

    6.1.1. Selective serotonin reuptake inhibitor (SSRI)

    6.1.2. Serotonin norepinephrine reuptake inhibitor(SNRI)

    6.2. Benzodiazepines

    6.2.1. Alprazolam

    6.2.2. Chlordiazepoxide

    6.2.3. Diazepam

    6.2.4. Lorazepam

    6.3. Others (Buspirone)

    7. Generalized Anxiety Disorder Market, By Geography

    7.1. Europe

    7.1.1. Germany

    7.1.2. France

    7.1.3. Italy

    7.1.4. Spain

    7.1.5. Russia

    7.1.6. U.K.

    7.1.7. Rest of Europe

    7.2. Asia Pacific

    7.2.1. China

    7.2.2. India

    7.2.3. Japan

    7.2.4. South Korea

    7.2.5. Rest of Asia-Pacific

    7.3. North America

    7.3.1. U.S.

    7.3.2. Canada

    7.3.3. Mexico

    7.4. Rest of the World (RoW)

    7.4.1. Brazil

    7.4.2. Rest of RoW

    8. Generalized Anxiety Disorder – Market Entropy

    8.1. Expansion

    8.2. Technological Developments

    8.3. Merger & Acquisitions, and Joint Ventures

    8.4. Supply- Contract

    9. Company Profiles (Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)

    9.1. GlaxoSmithKline Pharmaceuticals Limited

    9.2. Bristol-Myers Squibb

    9.3. Sumitomo Dainippon Pharma

    9.4. Noven Pharmaceuticals, Inc.

    9.5. Actavis Pharmaceutical Company

    9.6. F. Hoffmann-La Roche

    9.7. Abbott Laboratories

    9.8. Eli Lilly and Company

    9.9. Pfizer, Inc.

    9.10. Shionogi and Company

    *More than 40 Companies are profiled in this Research Report, Complete List available on Request*

    "*Financials would be provided on a best efforts basis for private companies"

    10. Appendix

    10.1. Abbreviations

    10.2. Sources

    10.3. Research Methodology

    10.4. Expert Insights

List Of Tables
in Generalized Anxiety Disorder Market: By Therapeutics Type(Antidepressant, Benzodiazepines, Others (Buspirone)) & Geography(Europe, Asia Pacific, North America, Rest of the World)-Forecast (2016-2021)

No

Additional Details

Publisher

Publisher Information

Reference

80183 | HCR 0216

Report Format

PDF

 Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Generalized Anxiety Disorder (GAD) Global Clinical Trials Review, H1, 2020
Generalized Anxiety Disorder (GAD) Global Clinical Trials Review, H1, 2020 SummaryGlobalData's clini...
08 May 2020 by Global Data USD $2,500 More Info
Generalized Seizures Global Clinical Trials Review, H2, 2019
Generalized Seizures Global Clinical Trials Review, H2, 2019SummaryGlobalData's clinical trial repor...
20 Dec 2019 by Global Data USD $2,500 More Info
2019 Generalized Seizures Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025
The global clinical trial report- “2019 Generalized Seizures Clinical Trials Study” provides complet...
24 Apr 2019 by VPA Research USD $1,799 More Info
Anti-depressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) - Global Opportu
Depression includes a variety of mental health problems characterized by the absence of a positive e...
01 Jan 2018 by Allied Market Research USD $3,840 More Info
Generalized Seizures Global Clinical Trials Review, H2, 2017
Generalized Seizures Global Clinical Trials Review, H2, 2017SummaryGlobalData's clinical trial repor...
30 Aug 2017 by Global Data USD $2,500 More Info
Generalized Seizures-Pipeline Insights, 2017
DelveInsight’s, “ Generalized Seizures-Pipeline Insights, 2017”, report provides in depth insights o...
30 May 2017 by Delve Insight USD $1,250 More Info
Generalized Tonic-Clonic Seizure-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Generalized Tonic-Clonic Seizure-Global API Manufacturers, Marketed and Phas...
30 May 2017 by Delve Insight USD $2,000 More Info
Panic Attack Treatment Market: By Panic Attacks Type (Generalized Anxiety Disorder, Obsessive-Compulsive Disorder (OCD), Others), By Drug (SSRI, SNRI, and BZD), & By Region-Forecast (2016-2021)
Panic attacks are associated with sudden surge of overwhelming anxiety and fear. Globally, developme...
14 Mar 2016 by USD $5,250 More Info

We Stock...